Advances in the studies of androgen metabolism and de novo androgen synthesis in castration resistant prostate cancer.
- Author:
Bin WANG
1
;
Kai-Jie WU
;
Da-Lin HE
Author Information
1. Institute of Urology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. february111@163.com
- Publication Type:Journal Article
- MeSH:
Androgen Antagonists;
pharmacology;
Androgens;
biosynthesis;
metabolism;
Humans;
Male;
Orchiectomy;
Prostate;
metabolism;
Prostatic Neoplasms, Castration-Resistant;
metabolism
- From:
National Journal of Andrology
2013;19(8):736-741
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer generally relapses into castration resistant prostate cancer (CRPC) after androgen deprivation therapy, which may be associated with androgen metabolism, particularly de novo androgen synthesis apart from the amplification and mutation of androgen receptor and the activation of its signaling pathways. This article focuses on the advances in the studies of the changes in androgen metabolism and de novo androgen synthesis in CRPC as well as their possible mechanisms and clinical significance.
